HYDERABAD: The state government is targeting a $250 billion life sciences economy by 2030 through the Telangana Next-Gen Life Sciences Policy 2026–30, which is set to be unveiled by Chief Minister A Revanth Reddy at the World Economic Forum (WEF) summit in Davos.
The policy will outline the strategic roadmap for the development of Green Pharma City. Officials said the Telangana Next-Gen Life Sciences Policy represents a statement of intent, positioning the state to shape the next phase of global life sciences and healthcare innovation.
Officials said that as the global life sciences sector undergoes rapid transformation, driven by advanced therapies, data-led discovery, precision medicine, and sustainability requirements, Telangana is seeking to move beyond scale and focus on value, innovation, and global integration.
The policy consolidates Telangana’s manufacturing base while accelerating its evolution into a competitive hub for advanced R&D, they added.
A major centre for pharma manufacturing
According to officials, Hyderabad hosts operations of several global pharmaceutical companies, including Eli Lilly, Sanofi, MSD, Novartis, Amgen, and BMS, among others. Contributing nearly 40% of India’s pharmaceutical production, Telangana has established itself over the decades as a major centre for pharmaceutical manufacturing.
Building on this base, the chief minister has outlined a role for Telangana on the global stage, with the state aiming to shape the future of healthcare and life sciences innovation. Telangana is developing a sustainable industrial cluster focused on pharmaceutical manufacturing and R&D.
The policy will also detail the roadmap for Green Pharma City. The Green Pharma City project integrates infrastructure with practices such as zero liquid discharge, centralised waste management, and energy-efficient systems.
Meanwhile, Telangana is a major life sciences hub in Asia, home to over 2,000 life sciences companies with a combined valuation of $80 billion. The state contributes nearly 40% of India’s pharmaceutical production, hosts over 250 USFDA-approved manufacturing sites, and accounts for about one-third of global vaccine output, earning it the tag of “Vaccine Capital” of the World.
Supported by infrastructure, policy support, a cluster-based ecosystem, and a skilled talent pool, Hyderabad has developed an innovation-oriented life sciences sector with over 20 life sciences and MedTech incubators.